Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 5Z-[(2E)-2-methyl-3-phenyl-d5-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
Purity: ≥99% deuterated forms (d1-d5)
Formula Markup: C15H8D5NO3S2
Formula Weight: 324.43096
Notes: Epalrestat-d5 is intended for use as an internal standard for the quantification of epalrestat (Item No. 15214) by GC- or LC-MS. Epalrestat is an inhibitor of aldose reductase (IC50s = 0.01 and 0.26 µM for rat lens and human placenta aldose reductase, respectively).{53254} It inhibits glucose-induced sorbitol accumulation in isolated rat lens, rat sciatic nerve, and human erythrocytes (IC50s = 1.5, 5, and 1.5 µM, respectively). It decreases high glucose-induced proliferation of vascular smooth muscle cells when used at a concentration of 10 nM and prevents high glucose-induced intracellular NADH/NAD+ increases and membrane-bound PKC activation at 100 nM.{24663,24664} Epalrestat (20 and 40 mg/kg) improves motor nerve conduction velocity and decreases sorbitol content in the sciatic nerve and erythrocytes in a rat model of streptozotocin-induced diabetic neuropathy.{53255} It also prevents capillary strand formation in a rat model of diabetes-induced retinal microangiopathy when administered at a dose of 50 mg/kg.{53256}
English
Deutsch
